
TerrAscend Stabilizes Cash Flow Amidst Cannabis Sector Volatility
TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call

TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Herbal Dispatch Advances U.S. Strategy amid Historic Cannabis Rescheduling Shift
Jushi Holdings Inc. Announces Proposed Continuance from British Columbia to Nevada
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Herbal Dispatch Reports Q4 2025 Gross Sales of $6.2 Million, Achieves Positive Adjusted EBITDA, and Reports Full Year Gross Sales of $16.5 Million
HYTN Announces Proposed Spin-Out of BPC-157 Peptide Drug Development Business
Cresco Labs CEO: Rescheduling Ushers in a New Era of Care for Medical Cannabis Patients
Verano Founder and Chief Executive Officer George Archos Celebrates Historic Announcement Confirming Cannabis Rescheduling to Schedule III
Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act
Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
Trulieve Applauds Trump Administration For Rescheduling Medical Marijuana to Schedule III
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector